Related Experiment Videos

Recent experience in the management of meningeal hemangiopericytomas

A Brunori1, A Delitala, G Oddi

  • 1Department of Neurosciences G.M. Lancist, San Camillo Hospital, Rome, Italy. brunoria@tin.it

Tumori
|January 16, 1998
PubMed

Insights

Meningeal hemangiopericytomas (HMP) have a poor prognosis, with high recurrence rates and significant impact on quality of life. Despite surgical and radiotherapy advances, outcomes for HMP remain dismal.

Area of Science:

  • Neurosurgery
  • Oncology
  • Pathology

Background:

  • Meningeal hemangiopericytomas (HMP) are distinct from meningiomas, though their origins are debated.
  • Recent data suggests HMP continues to present a significant clinical challenge.

Purpose of the Study:

  • To evaluate the current prognosis of intracranial meningeal hemangiopericytomas (HMP).
  • To assess the impact of modern treatment modalities on HMP outcomes.

Main Methods:

  • Retrospective review of 7 patients with HMP treated between 1986 and 1995.
  • Analysis of surgical outcomes, recurrence rates, and patient survival.

Main Results:

  • All but two patients experienced tumor recurrence, with a mean interval of 85 months.
  • Multiple surgeries were required (average 2.57 per patient).
  • Two patients had emergency surgery for hemorrhage; one developed visceral metastases.

Conclusions:

  • Intracranial hemangiopericytomas (HMP) have a dismal prognosis with high recurrence rates.
  • Advances in neurosurgery and adjuvant therapies have not significantly improved outcomes for HMP.

Related Concept Videos